237 related articles for article (PubMed ID: 20795788)
1. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
2. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE; Raphael BG
Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
[No Abstract] [Full Text] [Related]
3. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
4. Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I; Grossbard ML
Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
[No Abstract] [Full Text] [Related]
5. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
6. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
9. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
[TBL] [Abstract][Full Text] [Related]
11. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
12. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
Halene S; Zieske A; Berliner N
Nat Clin Pract Oncol; 2006 Mar; 3(3):165-8; quiz 169. PubMed ID: 16520806
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD52 in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
[TBL] [Abstract][Full Text] [Related]
15. The CD52 antigen and development of the CAMPATH antibodies.
Hale G
Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
[No Abstract] [Full Text] [Related]
16. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
Wong ET
Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
[TBL] [Abstract][Full Text] [Related]
17. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
18. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
19. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
